PTPN11突变对1529例急性髓系白血病患者临床结局的影响
该研究利用二代测序分析1529例成人AML患者,检出PTPN11突变106例(6.93%)。多因素分析显示PTPN11突变独立关联较差总生存、无复发生存及较低完全缓解率,其不良影响主要限于ELN预后良好组和亚克隆突变患者。
要点
- PTPN11突变在成人AML中检出率为6.93%,多伴随NPM1、DNMT3A和NRAS突变。
- PTPN11突变独立关联较差OS(HR 1.75)、RFS(HR 1.52)和较低CR率(OR 0.46)。
- 不良预后效应主要见于ELN预后良好组和亚克隆PTPN11突变患者,而主导性突变未见显著影响。
核心结论
- PTPN11突变在AML中总体提示不良预后,但该效应受细胞遗传学背景和克隆构型显著修饰。
研究设计与样本
- 研究纳入1529例成人AML患者,采用二代测序检测PTPN11突变并进行预后分析。
主要发现
- 106/1529例(6.93%)检出PTPN11突变,中位VAF为24%,主导性占36%、亚克隆占64%。
- PTPN11突变患者伴NPM1突变63%、DNMT3A突变37%、NRAS突变21%,ELN预后良好细胞遗传学比例更高(57.8% vs 39.1%,P<.001),白细胞计数更高(P=.007)。
- 多因素分析显示PTPN11突变独立关联较差总生存(HR 1.75,P<.001)、无复发生存(HR 1.52,P=.013)和较低完全缓解率(OR 0.46,P=.008)。
- 不良效应主要限于ELN预后良好组和亚克隆PTPN11突变患者(HR 2.28,P<.001),主导性突变未见显著关联(HR 1.07,P=.775)。
临床怎么用
- 对AML患者进行PTPN11突变检测时,应结合细胞遗传学风险和克隆构型(主导性 vs 亚克隆)解读其预后意义。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
The tyrosine-protein phosphatase nonreceptor type 11 (PTPN11) is an important regulator of RAS signaling and frequently affected by mutations in patients with acute myeloid leukemia (AML). Despite the relevance for leukemogenesis and as a potential therapeutic target, the prognostic role is controversial. To investigate the prognostic impact of PTPN11 mutations, we analyzed 1529 adult AML patients using next-generation sequencing. PTPN11 mutations were detected in 106 of 1529 (6.93%) patients (median VAF: 24%) in dominant (36%) and subclonal (64%) configuration. Patients with PTPN11 mutations were associated with concomitant mutations in NPM1 (63%), DNMT3A (37%), and NRAS (21%) and had a higher rate of European LeukemiaNet (ELN) favorable cytogenetics (57.8% vs 39.1%; P < .001) and higher white blood cell counts (P = .007) compared with PTPN11 wild-type patients. In a multivariable analysis, PTPN11 mutations were independently associated with poor overall survival (hazard ratio [HR]: 1.75; P < .001), relapse-free survival (HR: 1.52; P = .013), and a lower rate of complete remission (odds ratio: 0.46; P = .008). Importantly, the deleterious effect of PTPN11 mutations was confined predominantly to the ELN favorable-risk group and patients with subclonal PTPN11 mutations (HR: 2.28; P < .001) but not found with dominant PTPN11 mutations (HR: 1.07; P = .775), presumably because of significant differences within the rate and spectrum of associated comutations. In conclusion, our data suggest an overall poor prognostic impact of PTPN11 mutations in AML, which is significantly modified by the underlying cytogenetics and the clonal context in which they occur.
引用
- Stasik S, Eckardt JN, Kramer M, et al. Impact of PTPN11 mutations on clinical outcome analyzed in 1529 patients with acute myeloid leukemia. Blood Adv. 2021. PMID: 34459887. doi:10.1182/bloodadvances.2021004631
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。